RNA m6A changes in prostate cancer and treatment resistance
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancer
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-11310189
This work looks at how a common chemical change on RNA called m6A may drive prostate cancer growth and why some tumors stop responding to hormone treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-11310189 on ClinicalTrials.gov |
What this research studies
Researchers will examine how m6A RNA modification and the proteins that add or remove it influence androgen receptor signaling and prostate tumor behavior. They will use laboratory-grown prostate cancer cells, animal models, and likely patient tumor or blood samples to trace how m6A changes affect drug response. The team plans molecular assays to find which m6A-related molecules cause resistance to standard therapies like abiraterone and enzalutamide. Findings will guide ideas for new tests or treatments aimed at overcoming therapy resistance.
Who could benefit from this research
Good fit: Men with prostate cancer—especially those whose disease has become resistant to hormone therapies or who have metastatic/castration-resistant disease—would be the most relevant candidates to provide samples or consider future trials.
Not a fit: People without prostate cancer or those with early, localized disease unlikely to require advanced therapies may not receive direct benefit from this work.
Why it matters
Potential benefit: If successful, this work could point to new targets or biomarkers to prevent or treat drug-resistant prostate cancer.
How similar studies have performed: Laboratory studies have previously linked m6A changes to cancer cell behavior, but translating those findings into treatments for therapy-resistant prostate cancer remains an early and developing area.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEE, JIHOON — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: LEE, JIHOON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient, Cancers